---
title: "Alnylam Pharmaceuticals Surges 12% During Regular Trading on Competitor Drug Trial Failure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292211996.md"
description: "ALNY jumps 12% as Ionis-AZ heart drug trial fails, boosting competitor."
datetime: "2026-07-09T14:11:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292211996.md)
  - [en](https://longbridge.com/en/news/292211996.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292211996.md)
generator: "portal-rs"
---

# Alnylam Pharmaceuticals Surges 12% During Regular Trading on Competitor Drug Trial Failure

阿里拉姆制药 (ALNY.US) 盘中涨近**12%**，现报**361.18 美元**。

消息面上，Ionis Pharmaceuticals 与 AstraZeneca 合作的心脏病药物 eplontersen 在 III 期 CARDIO-TTRansform 研究中未能达到主要疗效终点，Ionis 股价盘前暴跌逾**21%**。阿里拉姆作为同一治疗领域的竞争对手，受益于竞品药物临床试验失利，股价大幅走高。

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

- [If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/297373977.md)
- [Alnylam to Webcast Investor Conference Presentations in September](https://longbridge.com/en/news/297781825.md)
- [Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility](https://longbridge.com/en/news/297493563.md)
- [Alnylam announces new data at ESC Congress on AMVUTTRA](https://longbridge.com/en/news/297453980.md)
- [Alnylam Pharmaceuticals misses Q2 street views](https://longbridge.com/en/news/294375290.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**